Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1997 Apr;50(4):320–323. doi: 10.1136/jcp.50.4.320

p53 gene product expression in resected non-small cell carcinoma of the lung, with studies of concurrent cytological preparations and microwave antigen retrieval.

S Binks 1, C A Clelland 1, J Ronan 1, J Bell 1
PMCID: PMC499883  PMID: 9215149

Abstract

AIM: To document the frequency and extent of p53 gene product expression in paraffin sections of resected non-small cell carcinoma of the lung and in cytological preparations of the same tumours; to determine the effect of microwave antigen retrieval on antigen detection. METHODS: Representative paraffin sections of 50 non-small cell carcinomas were stained with an antibody to p53 gene product (DO-7) both with and without prior microwave antigen retrieval. Cytoblocks and cell smears obtained from 19 cases were similarly stained. RESULTS: Using a histochemical scoring system (0-300) which takes into account staining intensity and extent, 78% (n = 39) of microwave pretreated paraffin sections and 52% (n = 26) of non-pretreated sections scored between 5 and 300; p = 0.001; 56% (n = 28) of microwave pretreated sections and only 2% (n = 1) of non-pretreated sections scored between 100 and 300 (p = 0.0001); 75% of direct smears of tumours and 80% of cytoblocks stained similarly to the paraffin sections of the resected specimens. No smears or cytoblocks stained positively when the sections of the resected specimen were negative. CONCLUSIONS: As up to 78% of non-small cell lung carcinomas overexpress p53 gene product, this may prove to be a valuable diagnostic method in biopsy or cytological material when the morphological diagnosis is uncertain. Microwave antigen retrieval is effective on formalin fixed tissue.

Full text

PDF
323

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caamano J., Ruggeri B., Momiki S., Sickler A., Zhang S. Y., Klein-Szanto A. J. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol. 1991 Oct;139(4):839–845. [PMC free article] [PubMed] [Google Scholar]
  2. Cattoretti G., Pileri S., Parravicini C., Becker M. H., Poggi S., Bifulco C., Key G., D'Amato L., Sabattini E., Feudale E. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993 Oct;171(2):83–98. doi: 10.1002/path.1711710205. [DOI] [PubMed] [Google Scholar]
  3. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  4. Dalquen P., Sauter G., Torhorst J., Schultheiss E., Jordan P., Lehmann S., Solèr M., Stulz P., Mihatsch M. J., Gudat F. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol. 1996 Jan;178(1):53–58. doi: 10.1002/(SICI)1096-9896(199601)178:1<53::AID-PATH415>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  5. Dowell S. P., Lane D. P., Hall P. A. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology. 1994 Apr;5(2):76–81. doi: 10.1111/j.1365-2303.1994.tb00530.x. [DOI] [PubMed] [Google Scholar]
  6. Dowell S. P., Wilson P. O., Derias N. W., Lane D. P., Hall P. A. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994 Jun 1;54(11):2914–2918. [PubMed] [Google Scholar]
  7. Ebina M., Steinberg S. M., Mulshine J. L., Linnoila R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 1;54(9):2496–2503. [PubMed] [Google Scholar]
  8. Fontanini G., Vignati S., Bigini D., Merlo G. R., Ribecchini A., Angeletti C. A., Basolo F., Pingitore R., Bevilacqua G. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol. 1994 Sep;174(1):23–31. doi: 10.1002/path.1711740105. [DOI] [PubMed] [Google Scholar]
  9. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  10. Korkolopoulou P., Oates J., Crocker J., Edwards C. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. J Clin Pathol. 1993 Dec;46(12):1093–1096. doi: 10.1136/jcp.46.12.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McCarty K. S., Jr, Miller L. S., Cox E. B., Konrath J., McCarty K. S., Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716–721. [PubMed] [Google Scholar]
  12. McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer. 1992 Oct;66(4):735–738. doi: 10.1038/bjc.1992.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Murakami I., Fujiwara Y., Yamaoka N., Hiyama K., Ishioka S., Yamakido M. Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1117–1123. doi: 10.1164/ajrccm.154.4.8887616. [DOI] [PubMed] [Google Scholar]
  14. Porter P. L., Gown A. M., Kramp S. G., Coltrera M. D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol. 1992 Jan;140(1):145–153. [PMC free article] [PubMed] [Google Scholar]
  15. Quinlan D. C., Davidson A. G., Summers C. L., Warden H. E., Doshi H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992 Sep 1;52(17):4828–4831. [PubMed] [Google Scholar]
  16. Soini Y., Kamel D., Nuorva K., Lane D. P., Vähäkangas K., Päkkö P. Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Arch A Pathol Anat Histopathol. 1992;421(5):415–420. doi: 10.1007/BF01606914. [DOI] [PubMed] [Google Scholar]
  17. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]
  18. Walker C., Robertson L. J., Myskow M. W., Pendleton N., Dixon G. R. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer. 1994 Aug;70(2):297–303. doi: 10.1038/bjc.1994.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Westra W. H., Offerhaus G. J., Goodman S. N., Slebos R. J., Polak M., Baas I. O., Rodenhuis S., Hruban R. H. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 1993 Mar;17(3):213–220. doi: 10.1097/00000478-199303000-00001. [DOI] [PubMed] [Google Scholar]
  20. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES